Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Acquires Imaxio's Genomics Business

NEW YORK (GenomeWeb News) – French biopharmaceutical firm Hybrigenics said recently that it has acquired the genomics business of biotech company Imaxio for an undisclosed amount.

Hybrigenics said that it received €1.3 million ($1.8 million) through a private placement from Pradeyrol Development to help finance the deal. Pradeyrol is a majority stakeholder in Imaxio.

Imaxio's genomic business is based in Clermont-Limagne Biopole, France and provides fee-for-service studies with a specialty in extracting and sequencing DNA and RNA. Hybrigenics said that it is one of a few European service providers certified by Agilent Technologies to perform SureSelect target enrichment, comparative genomic hybridization, and microRNA microarray technologies.

The facility is equipped with an Illumina sequencer, Hybrigenics added.

Hybrigenics CEO Remi Delansome said in a statement, "The acquisition of the genomics division of Imaxio gives Hybrigenics a foothold in the booming market of genomic services and the investment by Pradeyrol Development is providing resources to develop this new business. In addition, commercial synergies with Hybrigenics Services' proteomics activities will be fostered."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.